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Abstract
Background: The distribution of the enzymopathy glucose-6-phosphate dehydrogenase (G6PD) deficiency is linked
to areas of high malaria endemicity due to its association with protection from disease. G6PD deficiency is also
identified as the cause of severe haemolysis following administration of the anti-malarial drug primaquine and
further use of this drug will likely require identification of G6PD deficiency on a population level. Current
conventional methods for G6PD screening have various disadvantages for field use.
Methods: The WST8/1-methoxy PMS method, recently adapted for field use, was validated using a gold standard
enzymatic assay (R&D Diagnostics Ltd ®) in a study involving 235 children under five years of age, who were
recruited by random selection from a cohort study in Tororo, Uganda. Blood spots were collected by finger-prick
onto filter paper at routine visits, and G6PD activity was determined by both tests. Performance of the
WST8/1-methoxy PMS test under various temperature, light, and storage conditions was evaluated.
Results: The WST8/1-methoxy PMS assay was found to have 72% sensitivity and 98% specificity when compared to
the commercial enzymatic assay and the AUC was 0.904, suggesting good agreement. Misclassifications were at
borderline values of G6PD activity between mild and normal levels, or related to outlier haemoglobin values (<8.0
gHb/dl or >14 gHb/dl) associated with ongoing anaemia or recent haemolytic crises. Although severe G6PD
deficiency was not found in the area, the test enabled identification of low G6PD activity. The assay was found to
be highly robust for field use; showing less light sensitivity, good performance over a wide temperature range, and
good capacity for medium-to-long term storage.
Conclusions: The WST8/1-methoxy PMS assay was comparable to the currently used standard enzymatic test, and
offers advantages in terms of cost, storage, portability and use in resource-limited settings. Such features make this test
a potential key tool for deployment in the field for point of care assessment prior to primaquine administration in
malaria-endemic areas. As with other G6PD tests, outlier haemoglobin levels may confound G6PD level estimation.
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Background
Malaria has exerted the greatest genetic pressure on the
human genome in recent times, resulting in the evolu-
tionary selection of genetic mutations that confer pro-
tection against the disease [1-4]. Glucose-6-phosphate
dehydrogenase (G6PD) is an X-linked recessive here-
ditary disorder that currently affects 200–400 million
people worldwide, with over 160 mutations identified
[3-6] and there is pronounced geographical overlap be-
tween areas of G6PD deficiency prevalence and malaria
endemicity [2,7-15]. The G6PD gene codes for an en-
zyme responsible for catalyzing nicotidamine adenine
dinucleotide phosphate (NADP+) to its reduced form,
NADPH, in the pentose phosphate pathway. Among
G6PD variants with reduced enzyme activity, several
phenotypic effects have been described, and are classi-
fied by the WHO as: enzyme deficiency with chronic
non-spherocytic anaemia (class I, <10% activity); severe
enzyme deficiency (class II, <10% activity); moderate/
mild enzyme deficiency (class III, 10-60% activity); very
mild or no enzyme deficiency (class IV, >60-100% acti-
vity); and increased enzyme activity (class V, >150%
activity) [16]. Erythrocytes with insufficient G6PD are
thus unprotected against oxidative injury, and individ-
uals with G6PD deficiency may develop haemolytic an-
aemia in response to a number of stresses, including
infection and exposure to medications such as the 8
amino-quinoline, primaquine [17].
Primaquine has received renewed interest in the con-
text of malaria eradication. The drug is recommended as
presumptive anti-relapse treatment of Plasmodium vivax
and Plasmodium ovale infection due to its activity
against hypnozoites. Furthermore, it remains the only
readily-available drug that actively clears mature P.
falciparum gametocytes [18-22]. Given the risk of haem-
olysis in G6PD deficient individuals, and the genetic and
phenotypic variability of G6PD deficiency across geo-
graphic areas where primaquine treatment is consid-
ered, estimation of G6PD enzyme function prior to drug
administration is recommended [23]. At present, how-
ever, primaquine therapy without prior determination of
G6PD enzyme function, perhaps due to a lack of reliable
tests, is thought to be common [24].
One possible reason for the current lack of a standard
diagnostic test is that the majority of methods for
assessing G6PD deficiency have shortcomings for field
use in tropical countries [25-27] (see Table 1). In 2003, a
novel enzymatic method to detect G6PD deficiency was
developed [28], based on the WST8 tetrazolium salt and
the 1-methoxy PMS hydrogen carrier. The assay has re-
duced light sensitivity, and is easily interpretable, both
quantitatively and qualitatively. In 2010 Kuwahata et al.
reported a version of this method, optimized for use in a
96-well plate format using dried bloodspots in filter
paper, which was successfully tested as an in-field mass-
screening tool for G6PD deficiency in the Solomon Islands
[25]. The aims of this current study were to further vali-
date the WST8/1-methoxy-PMS test by comparison with
a commercially available enzymatic reference test and to
assess the test’s robustness for field use.
Methods
Study site & sample selection
The study was conducted in seven sub-counties (Nagongera,
Paya, Kirewa, Kisoko, Petta, Mulanda, and Rubongi) in
Tororo district, an area with very high malaria transmis-
sion intensity in Uganda. In August-September 2010, the
study area was mapped and a census survey carried out.
Households within 2 km of a health facility were included
in the sampling frame. Children under the age of five years
were recruited from randomly selected households and
were enrolled into a cohort study (Clinical Trials registra-
tion number NCT01024426) if they met the following in-
clusion criteria: 1) age < 5 years, 2) agreement of parents
or guardians to provide informed consent, 3) no intention
to move during the follow-up period. Clinical and labo-
ratory evaluations were conducted at enrolment and re-
peated every six months over the period of follow-up.
Blood samples collected from cohort study participants at
follow-up visits conducted in July and August 2011 were
used for the G6PD study.
Laboratory procedures
Blood samples were collected by finger-prick, onto 3MM
filter paper, and were dried at ambient temperature. Sam-
ples were then stored at room temperature in zip-lock
bags containing silica desiccant beads, and assayed
within 24-72 h. The remainder of the sample was stored
for various time periods and temperature/illumination
conditions for further evaluation. Additionally, hae-
moglobin values were obtained using a HaemoCue B
analyser. In parallel, two sets of internal controls were
generated to calibrate the assay. A commercial standard
reagent of known G6PD activity (Trinity Biotech Nor-
mal Control) was used to create a panel of normal,
moderate, and severe deficiency (100%, 30% and 10% ac-
tivity respectively), as well as a no-enzyme control (0%).
The second set of internal controls was generated from
human blood from two volunteers with normal G6PD
activity, and followed the procedure described for the
field-adapted test [25]. Each set of controls were spotted
onto 3MM filter paper (Whatman), and stored under
the same conditions as the samples. Blood spots and
controls were tested by both the optimized WST8/1-
methoxy PMS assay, and by the commercially available
standard R&D® test. Results were evaluated both visually
and quantitatively.
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WST8/1-methoxy PMS assay
The principle of the WST8/1-methoxy PMS method de-
pends on reducing hydrogen from NADPH converting
WST8 to WST8-formazan in the presence of the hy-
drogen carrier 1-methoxy-PMS. This reaction yields a
strong easily detectable orange colour, with colour in-
tensity directly proportional to G6PD activity. After a
2 hr incubation at room temperature, samples with nor-
mal G6PD activity show strong orange colour, deficient
samples show faint colour (moderate deficiency likely to
represent heterozygotes) or no colour (severe deficiency
& negative controls).
Two stock solutions were prepared: a working mix,
and a control mix. The working mix contained 50 mM
G6P (Roche), 4 mM NADP (Merck Pty Ltd), 1M Tris–
HCl pH 7.2-7.5, and 100 mM MgCl2 (Sigma-Aldrich).
The control mix contained all reagents in the concen-
trations described above, but lacked NADP and G6P.
Mixes for assay development consisted of 0.5 mL of
WST8/1-methoxy PMS (Dojindo Laboratories), 0.5 mL
of working stock solution, and 19mL of distilled water
for every 96-well plate. Negative controls were gener-
ated on site as described in previous studies [25].
A 1.5 mm diameter disc was punched out from each
blood spot sample and placed inside a single well of the
96-well flat bottom microplate. Samples were assessed
in duplicate. Plates were incubated for 2 h at ambient
temperature, and were then inspected by eye by two
different observers for qualitative analysis. For quantita-
tive analysis, the optical density was quantified in a
microplate reader (Multiskan EX, Thermo scientific) at
wavelength OD450-594 nm. G6PD levels were deter-
mined in reference to the control panels.
Reference assay: standard quantitative G6PD assay (R&D®
diagnostics)
The R&D® colourimetric test was used for validation
[29,30]. In this test, the resulting NADPH reacts with a
colour reagent in which a formazan salt (nitrotetrazolium
blue) is produced, generating a visually detectable purple
colour. The resulting OD (measured at 550 nm), is pro-
portional to the level of G6PD present in the dried sample.
Table 1 Available tests for determination of G6PD deficiency and their use in field settings
Test Characteristics Shortcomings for field and mass-screening
DNA sequence analysis of the
G6PD gene.
Extremely reliable. Primers are used to check whether
the G6PD gene contains a mutation.
Requires training, and equipment. Genotype does not
correlate with enzyme function and the risk of
haemolysis. Female heterozygous have unpredictable
phenotype due to X chromosome lyonization. Only
one mutation can be analysed with one primer
(>160 mutations exist).
Brilliant cresyl blue decolouration
test
Involves the action of G6PD and NADPH diaphorase.
A deficiency of either one of these enzymes on RBCs
would result in the brilliant cresyl blue remaining
unchanged in the test.
Laborious processes; requires technical skill, and has
low sensitivity.
Methaemoglobin reduction test Based on the oxidation of Hb to MetHb by sodium
nitrate and the subsequent enzymatic reconversion to
Hb in the presence of methylene blue.
Laborious, qualitative and low sensitivity. Does not
enable identification of heterozygous deficient females.
Formazan ring method Uses the principle of the MTT-Linked spot test. When
G6PD is present at normal levels, MTT is reduced to a
purple insoluble formazan derivative, and results in a
specific diameter of discolouration.
Prone to misdiagnosis.Ring thickness may be affected
by exogenous factors.
Sephadex gel MTT-PMS method Mostly used in Asia, and predecessor in concept, of
the WST8/1-methoxy PMS test.
Reacts with haemoglobin; is light sensitive and water
insoluble. It is of a qualitative nature.
Fluorescent spot test (FST) ICSH-recommended method. Its cut-off value for G6PD deficiency determination is
only 10-20% of the normal G6PD activity, which
excludes patients with moderate enzyme deficiency
and increases the risk of false-normal diagnosis.
BinaxNOW® rapid test Rapid test format: Overcomes issues of technical skill,
sophisticated equipment and reliability.
It is highly dependent on temperature-sensitive kinetic
enzymatic reactions. This limits its use to areas with
temperatures between 18 and 25C. Potential cost.
CareStart™ test RDT format. Qualitative chromatographic test, based in
the reduction of colourless nitro blue tetrazolium dye to
dark colour formazan. Long-term temperature stability.
Potential cost.
R&D® enzymatic test (reference) Both depend on the conversion of NADP + to NADPH
by G6PD. NADPH converts colourless tetrazolium salt
into a coloured formazan, while NADP + does not.
Enzymatic gold standard. Requires various temperature-
dependent incubations.
WST8/1-methoxy PMS test
(test under validation)
Evaluated in this work. Advantages: no reaction with
haemoglobin, lower light sensitivity.
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The assay was performed using 96-well plates and dried
blood-spots in filter paper as per manufacturers instruc-
tions. The same sets of controls were used for both assays,
and their robustness tested under various temperature,
storage and light conditions.
Experiments to assess assay robustness
Storage
Storage of 150 dried blood spots (FPBS) prior to develop-
ment of the assay was done at 24°C and 4°C and tested at
days 1, 2, 4, 5, 9, and 10 post-collection. Working mixes
were stored at 24, 4, and −20°C, and tested at weeks 1,2
and 3.
Reaction stability
Control assays were developed for 2 hrs at 3 different tem-
peratures (37°C, 24°C and 10°C) to determine whether the
kinetics of the assay was affected by temperature. Given
the identification of limitations related to storage at room
temperature of blood-spots in filter paper previously
reported [25], a selection of samples were assayed 24 h
after collection of the sample, and frozen at −20°C imme-
diately after absorbance was quantified. They remained
frozen for 1, 2, 3 and 4 weeks before G6PD assessment
was carried out again both qualitatively and quantitatively.
Light
The 2 hr development of assays for G6PD determination
was done under various light conditions: in the dark,
scattered light (indoors), and direct exposure to sunlight
(outdoors).
Filter paper use
Assays for filter-paper saturation with blood-spots were
done for both the WST8/1-methoxy PMS assay and the
standard test, to assess whether or not significant differ-
ences in saturation could affect G6PD level determination.
Such assessment was done by perforating 5–6 blood spots
with different levels of saturation from the filter paper,
and comparing the final quantitative readout.
For all measurements, the same preliminary experi-
ments to those carried out with the WST8/1-methoxy
PMS assay were reproduced with the standard refer-
ence test.
Sample size
The sample size was computed based on G6PD deficiency
prevalence previously calculated by two independent stu-
dies in Kampala (16%) [31,32]. To validate the WST8/1-
methoxy PMS method by comparison to the reference test
with 80% power, the minimum number of samples cal-
culated was 108. The final number of samples compared
was 122, and a further 113 samples were evaluated by the
WST8/1-methoxy PMS method alone.
Data entry and statistical analysis
Data regarding clinical evaluations, and G6PD assay out-
comes were double-entered and validated. Visual analysis
was done independently by two observers. Agreement
scores between observers, G6PD level visual determin-
ation, and quantitative data were produced, and analysed
with STATA version 11 (STATA Corporation, College
Station, TX). For analysis of the use of the two tests, a
contingency table was produced and sensitivity, specificity,
PPV and NPV were calculated. A Receiver Operating
Characteristic (ROC) curve was calculated. Potential char-
acteristics that could affect G6PD deficiency assessment
including gender, age, haemoglobin levels, and prevalence
of anaemia were tested by univariate and multivariate
regression analysis. Agreement between observers regard-
ing qualitative G6PD activity levels by the WST8 assay,
and the R&D reference test was determined by calculating
a weighted kappa (Kw) value. A p-value < 0.05 was consid-
ered as statistically significant.
Ethics
Ethical approval to perform the G6PD assay validation
was obtained from the London School of Hygiene and
Tropical Medicine Ethics Committee (application no.
010/361). The use of human participant samples from
the ACT PRIME study was under ethical approval of the
Makerere University School of Medicine Research and
Ethical Committee (no. 2010–108), the Ugandan National
Council for Science and Technology (no. HS 794), the
LSHTM Ethics Committee (no. 5779), and the University
of California San Francisco (no. 006160).
Results
WST8/1-methoxy PMS test use in a field setting
Timeframe and temperature storage conditions affect assay
performance
Bloodspot storage Following collection, a random selec-
tion of 150 FPBS were stored at two different tempera-
tures (4°C and 24°C), and assayed at various days (1, 2, 4,
5, 6, 9, 10) to determine optimal storage times before deg-
radation of G6PD occurs and risk of misclassification
increases. G6PD enzymatic activity could still be accur-
ately assessed 10 days after sample collection with storage
of blood spots at 4°C. Beyond this timeframe, the risk of
misclassification increased (Figure 1a). For samples stored
at room temperature, enzyme degradation occurred at a
faster rate than previously reported [25], and classification
at day 5 post-sample collection was not possible due to a
high degree of misclassification (Figure 1b).
Assay mix storage The stability of assay concentrated
mixes was evaluated for a three-week time frame follow-
ing storage at room temperature, 4°C and −20°C. Assays
were then developed and ODs measured at time 0, and
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weeks 1, 2, and 3. Results for assay mixes stored at room
temperature and 4°C were comparable to those obtained
by Kuwahata et al. [25]. Results for assay mixes stored
at −20°C yielded comparable results to those obtained
using fresh mixes at all time points evaluated.
Assayed plate storage post-development As the stor-
age time of blood spots prior to assay was limited due to
enzyme degradation, developed plates were re-assayed
after initial assessment, after storage at −20°C for various
time points including 24 hours, 1, 2, 3 and 4 weeks.
Figure 2 shows that both visual and quantitative assess-
ment of samples evaluated using the WST8 test was
possible at all time points.
Temperature and scattered light had little effect on G6PD
classification and assay performance
Half-hourly kinetics of assays developed at 10, 24 and
37°C were measured and shown in Figure 3a. It was
observed that G6PD level assessment and classification
was not compromised across temperature ranges,
although G6PD level assessment at 10°C was complicated
(Figure 3a). In terms of assay sensitivity to aberrant col-
ouration due to light, exposure of the assay to scattered
light had little effect on abnormal colour development
during a 2 hr period, however, direct exposure to UV light
led to aberrant colour development (Figure 3b).
Test validation by comparison to reference test
High inter-observer reliability exists for qualitative
classification of G6PD levels using the WST8 test
A weighted kappa statistic (Kw) for inter-observer reliability
(based on qualitative G6PD classification by two observers
visual assessment) was calculated to be 0.922, indicating
excellent agreement. Paired assessment was conducted for
122 samples. Most mismatches between observers occurred
for samples with G6PD levels with threshold values be-
tween mild deficiency (30-60% activity) and normal activity.
Such range of G6PD levels is not of significant clinical rele-
vance. A 90% agreement between both observers and the
quantitative estimation of enzyme activity was calculated,
and 10% discordance in samples with borderline G6PD
Figure 1 Enzyme degradation due to storage on filter papers. a) 150 filter papers with control blood spots with normal activity, moderate
deficiency, severe deficiency, and no enzyme (100%, 30%, 10%, and 0%) were stored for up to 10 days at 4°C, and their activity measured at days
1,2,4,6,9, and 10. b) Samples were stored at room temperature, in the dark, for days 1–5, and the activity measured daily.
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values (at the normal/moderately deficient threshold) was
found. Importantly, moderate and severe deficiency values
were always accurately classified. It was observed that
fresh human blood controls led to an estimation of a
significantly higher percentage of G6PD deficient samples
(in the 10-20% activity range), than the commercial con-
trol (p < 0.05). Controls with similar storage time-frames
as the samples being tested were used, in order to prevent
misclassification due to higher or lower reference OD
values, as has been also reported elsewhere [25,30,33].
Figure 3 Assay kinetics at various temperature and light levels. a) G6PD activity measured after 2 hr development at 37°C, 24°C, and 10°C.
Classification of G6PD values was possible at all temperatures, with 10°C showing the least variation Results repeated 3× in duplicate (p > 0.05).
b) Colouration development in reagents only, following 2 hr incubation outdoors (exposure to sunlight), and indoors (exposure to scattered
light). Aberrant colouration measured at the same wavelength as the G6PD assay (OD 450 nm) was detected.
Figure 2 Temperature effects on storage of developed assays. G6PD activity was measured by the WST8/1-methoxy PMS test on fresh
samples. The developed assay was then stored at −20°C for 24 h, and 1–4 weeks.
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The WST8/1-methoxy-PMS test has high agreement with the
reference test
Agreement values between the WST8/1-methoxy-PMS
assay and the reference R&D test were assessed using
the categorization of G6PD enzyme function into a)
severe deficiency (<10% G6PD activity), moderate defi-
ciency (10-30%), mild deficiency (30-60%), and normal
activity (60-100%). Results are shown in Table 2. There
was 100% agreement in classification of severe, moder-
ate, and >150% activity samples. The lowest agreement
recorded occurred near the cut-off point between nor-
mal and mild deficiency values (40-60% enzyme activity).
Importantly, both the WST8 test, and the R&D test
enabled identification of individuals with low G6PD
enzyme activity with the highest risk for haemolytic
anaemia (<30% activity). Using the R&D test as a refer-
ence standard, the WST8 test’s overall sensitivity for
G6PD normal or G6PD deficient was found to be 72%,
specificity 98%, PPV 91.3%, NPV 91.9%. The overall
percentage of correct diagnosis was 91.8%, and an AUC
value of 0.904 was calculated (Figure 4).
Study population and assessment of G6PD enzymatic
activity
Samples from 235 children (110 females, 125 males) were
analysed. No significant difference in G6PD deficiency
levels between males and females was found (p = 0.136) by
either the WST test or the reference R&D test. Among
the male children, 16.5% showed intermediate levels of
G6PD activity (Figure 5). Mean age and age distribution
was similar among all G6PD classes (normal, mild, moder-
ate and low deficiency) (p = 0.802). No severe deficiency
was detected in this study population. While children with
severe G6PD deficiency were not seen, G6PD values as
low as 10.3% activity were identified. Anaemia prevalence
(defined in this case as Hb levels under 10g/dl) was not
significantly different between G6PD classes (p = 0.072).
However, overall haemoglobin levels between the 3 main
G6PD classes was significantly different (p = 0.022), with
general haemoglobin levels being lower in G6PD normal
children (Table 3).
Discussion
Susceptibility of G6PD deficient individuals to haemoly-
sis caused by anti-malarial drugs such as primaquine
and other 8-aminoquinolines is a concern for worldwide
efforts for malaria eradication, given the geographical
overlap between malaria-endemic areas and those po-
pulations with high prevalence of G6PD deficiency
[12,13,27]. While primaquine administration without
G6PD screening for confirmed malaria cases is thought
to be relatively common, ethical issues regarding the use
of the drug are regaining attention as wider community
use is considered. At present, a main limitation for
wide-scale implementation of G6PD screening is the lack
of a robust, low-cost and rapid test that can accurately
classify the majority of samples obtained from indivi-
duals in a steady state (ie. not suffering from haemolytic
anaemia at the time of test), and that enables testing of a
large number of samples simultaneously. In 2003, Tantular
and Kawamoto published a simple screening method for
detection of G6PD deficiency based on enzymatic activity,
with improved performance and reagent stability com-
pared to its predecessors [28]. Additionally, the method
offers the advantage of enabling both qualitative and
quantitative assessment of G6PD levels based on the
NADPH concentration in the test, which yields strong
colouration. Since its description in 2003, the assay has
been used in various settings, including Thailand [12]
and Suriname [26]. In 2010, Kuwahata et al. successfully
optimized the WST8/1-methoxy PMS assay for field use
by adapting it to a 96-well plate format, and dried
blood-spots in filter paper. The optimized test was suc-
cessfully used to determine G6PD deficiency prevalence in
Isabel Province, Solomon Islands [25]. Given the observa-
tions previously described regarding the performance of
the WST8 test, the aims of this study were to validate the
WST8 method in relation to a standard reference enzym-
atic test (commercially available R&D); and to identify
operational shortcomings and advantages of this test for
use in field and resource-limited settings.
The assay was found to be easy to use, with low use of
consumables, and low requirements for sophisticated
equipment, as well as being less time consuming than
the reference test. On average, processing time for a 96-
well plate worth of samples took 10 minutes of active
processing and a 2 hr waiting period for development,
while the R&D test took 1 hour of active processing.
The WST8 test was not overly affected by temperature
variation, and the temperature range within which
Table 2 Detection of G6PD deficiency levels: agreement and validation of WST8/1-methoxy PMS test
WST8/1-methoxy PMS Standard colourimetric test Agreement (%)
Total samples tested 122 122 -
Normal activity 98 (80.4%) 94 (77.04%) 92.63%
Mild deficiency (30-60% activity) 15 (12.3%) 21 (16.4%) 96.72%
Moderate deficiency (10-30% activity) 9 (7.38%) 9 (7.38%) 100%
Severe deficiency (<10%) 0 (0%) 0 (0%) 100%
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accurate G6PD classification was possible, includes tem-
peratures generally observed in tropical areas. Similarly,
the test was less sensitive to scattered light in the la-
boratory than previously reported for other tests. Never-
theless, from our observations, we suggest avoiding
unnecessary exposure of the test and the reagents to
light for extended periods. In terms of storage of assay
mixes and reagents, our conclusions are similar to those
previously reached by Kuwahata et al. and confirm that
long-term storage is advantageous for assay transport
and assay use in field settings where assays may need to
be run in the field, and subsequently tested in a central
laboratory. This is likely, as a major limitation for stor-
age is that enzyme degradation occurs in blood spots in
filter papers limiting the time they can be held prior to
testing. Previously, Kuwahata et al. determined that
accurate G6PD classification could be done by the
WST8 method on filter papers stored at ambient
temperature for no more than five days, or alternatively
at 4°C for up to 10 days. This is similar to the findings
of this study for storage of samples at 4°C, yet storage of
samples at room temperature for more than four days
led to G6PD level misclassification. It is thus
recommended that the samples be tested within 48-72h
following sample collection, given that degradation time
may vary slightly among different settings after this time
frame. An alternative is the possibility to freeze assayed
plates at −20°C for quantitation at a later time point. Al-
though this requires freezing facilities, it would allow
subsequent mass testing of samples for confirmation of
visual readings. A key observation from this and previous
studies [30], is that a control panel, which comprises
Figure 4 Validation of the WST8/1-methoxy PMS assay (AUC). Receiver operating characteristic curve for the performance of the WST8/1-methoxy
PMS test for G6PD diagnosis in the field study in Uganda.
Figure 5 G6PD distribution by gender. a) Among 110 females, 84.5% had G6PD levels ranging from 60% to 123% activity; 9.37% of females
had G6PD activity lower than 30% - the activity threshold established by the WHO as posing a risk for primaquine administration at the present
regime. Most females had activity values between 60 and 80%. b) Among 125 males, 76.8% had G6PD levels ranging from 40.3% to 137.8%. 9.4%
of males had values lower than 30% activity. Most males had activity values in the 60-70% range.
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positive controls and various levels of relative G6PD con-
centrations, should be stored in similar conditions to
those of samples to be tested, as this will reduce the risk
of misclassification. Two other observations, common to
spectrophotometric assessments with FPBS were that both
blood spot saturation and bubbles in the microplate wells
can adversely affect reactions leading to aberrant read-
ings and underestimation of G6PD levels. Overall, it was
found that the WST8 assay offered major advantages in
relation to other currently-used G6PD screening tests in
its suitability for field use.
Importantly the assay also performed well. In compari-
son with the standard reference test, the WST8 test had
72% sensitivity, 98% specificity, and an AUC value of
0.904. The sensitivity of the test was only with misclassi-
fications corresponding to samples with values between
normal enzyme activity and mild G6PD deficiency i.e.
individuals not at risk of severe haemolytic anaemia after
treatment with primaquine (ie. >30% enzyme activity as
defined by the WHO). Current tests, including the ICSH
recommended fluorescent spot test (FST) method, re-
port a sensitivity value as low as 32% [27,34-36]. In this
context, the WST8 test enabled accurate identification
of a wide range of G6PD enzyme levels. The study also
showed a good inter-observer reliability (qualitative as-
sessment) with very good agreement in relation to the
quantitative classification though numbers of observers
and samples were relatively few.
A known confounder for G6PD tests is haemoglobin
concentration. This may be potentially attributed to the
fact that in patients with haemolytic anaemia, older
erythrocytes are haemolysed, while the remaining retic-
ulocytes have normal or near-normal enzyme activity.
Previous G6PD screening studies have therefore sug-
gested that G6PD testing must be done in parallel with
haemoglobin measurements [25,33], or that inbuilt
haemoglobin normalization must be considered for ac-
curate determination of status [30]. In this study, base-
line haemoglobin measurements in G6PD normal and
G6PD-deficient children were significantly different by
univariate analysis. The lower haemoglobin levels in
children with normal G6PD in this study may be attri-
butable to G6PD deficiency being associated with a pro-
tective effect against infections that may result in
anaemia, however, the study was not powered to test
this effect. Importantly, no severe deficiency was
detected in this study population using both the refer-
ence and WST8 tests, which is in agreement with the
expected G6PD A- prevalent genotype in Africa [5,8].
In conclusion, the WST8 test offers some important ad-
vantages in comparison to other tests for G6PD deficiency
assessment in large-scale screening studies and public
health interventions where primaquine administration is
being considered. As demonstrated by this study, G6PD
screening using the WST8 assay can be easily nested into
other public health interventions, which is advantageous
for its inclusion in malaria elimination programmes
contemplating the use of primaquine. Additionally, the
high comparability of quantitative and qualitative G6PD
estimates between the WST8- and the standard colorimet-
ric tests used for diagnosis in hospital settings, suggest
that the WST8 test would be a relatively safe basis for
clinical decisions. This would obviously depend on
existing clinical and laboratory capacity in any facility and
require some adaptation to single sample testing [37]. No
individuals with severe deficiency were identified in this
study. Although this is a limitation in terms of validation
of the test, a previous study carried out in the Solomon
Islands with the WST8 test [25], enabled the identification
of severely G6PD deficient individuals, as well as a range
of G6PD activities similar to the one reported here. In
order to fully assess the capacity of the test in various field
settings, further studies in various geographical locations
where diverse G6PD genotypes are prevalent, would be
advantageous. A further key observation is the need for
parallel haemoglobin determination, emphasized in previ-
ous G6PD deficiency assessments [25,26,30,33]. This is
likely to be of general benefit both in assessing the inter-
pretability of the test and also may indicate other causes
of anaemia and any required treatment. Overall, the
Table 3 Baseline measurements and G6PD classification by the WST8/1–methoxy PMS test
Glucose–6–phosphate dehydrogenase classification
Normal
(40–100 + % act.)
Moderate
(mild: 20–40% activity)
Moderate
(low: 10–20% activity)
Summary statistic
(univariate normal/deficient)
Total
Number 235
Males (n) 96 21 8 p = 0.136 125 (53.2%)
Females (n) 93 10 7 110 (46.8%)
Age (years, range) 2.83 (0.1–5.3) 2.89 (0.01–5.8) 2.87 (0.01 –5.1) p = 0.802 2.84 (0.01 – 5.8)
Hb level (g/dl, mean, range) 11.18 (4.9–14.9) 11.74 (8–16) 11.90 (8.8 – 17) p = 0.022 11.3 (4.9 – 17.0)
Anaemia (%) 28.57 16.12 20.0 p = 0.072 26.4%
G6PD activity (%, range) 72.6 (40.3–137.8) 29.2 (20.5–39.6) 15.11(10.3–19.8) n/a 63.2 (10.3–137.8)
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WST8 test has a considerable potential as a diagnostic tool
prior to primaquine administration in malaria-endemic
areas as a point of care test and/or as a screening tool for
assessing G6PD prevalence in large-scale screening studies
in areas contemplating primaquine deployment.
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